The global joint pain injections market was valued at $6,271.91 million in 2021, and is projected to reach $13,176.31 million by 2031, registering a CAGR of 7.7% from 2022 to 2031.
Joint pain injections refer to the non-surgical procedures that involves application of the medication directly to damage joint tissue. Joint pain is defined as the discomfort caused into the joints which is associated with the various reasons including the arthritis and its different kinds, the previous injuries to a joint, overuse of the muscle, depression, anxiety, stress, and obesity. Furthermore, interleukin inhibitors are one of the most common types of therapeutic injections that include an anesthetic agent combined with a corticosteroid to relieve joint pain and inflammation.
According to the Arthritis Foundation, as of the numbers generated in 2022 there are about 60 million adults who have been diagnosed with arthritis and 1 in 4 adults have one of these types of arthritis. This rise in incidence of arthritis among all age groups owing to a sedentary lifestyle, rise in obesity, injuries due to physical activities and stress, will lead to the sales of the joint pain injection on a large scale.
Furthermore, the joint pain injections market is anticipated to grow by the introduction of numerous cutting-edge treatment technologies by the pharmaceutical companies, an increase in the demand for accurate treatment options by the patients, and the availability of high income in the developed economies.
Arthritis Foundation also states that, the inflammatory and rheumatic diseases that develops in children under the age of 16 is known to be juvenile arthritis, which affects nearly 300,000 kids and teens in the U. S. However, the government of Australia has published ‘The National Strategic Action Plan for Arthritis’ that aims to guide national efforts to address the burden of arthritis. Thus, such more initiatives and funding provided by the government will boost the growth of the market.
In addition, the rise in investment for research and development of the advanced and precise treatment options by public and private players in the market with an aim to improve health care infrastructure, due to the rise in the prevalence of the arthritis, along with rise in the obesity and geriatric patients are the key factors for the expansion of the joint pain injections market. For instance, the U. S. FDA approval for the second indication for Skyrizi (risankizumab-rzaa) to treat adults with active psoriatic arthritis that can be administered with a single injection four times a year.
However, the market is expected to be significantly constrained in the near future by factors such as lack of awareness about these injections in developing nations, their expensive price, and lack of reimbursement policies that effects the adoption of the products in the emerging countries. However, the key market players are developing more efficient treatment options which includes the single injection therapy and plasma matrix therapy, which will provide lucrative opportunities during the forecast period.
The joint pain injections market is segmented on the basis of injection type, by joint type, by distribution channel and region. By injection type, it is divided into interleukin inhibitors, hyaluronic acid injections and others. On the basis of joint type, the market is segmented into knee & ankle, hip joint, shoulder & elbow, facet joints of the spine and others. According to the distribution channel, the market is segmented into hospital pharmacies, drug stores & retail pharmacies and online providers. Further, the hospital pharmacies segment is divided into public hospital pharmacies and private hospital pharmacies. Region wise, it is analyzed across North America, Europe, Asia-Pacific, and LAMEA.
The major companies profiled in this report include Abbvie Inc., Anika Therapeutics Inc., Bioventus Inc., Eli Lilly and Company, Ferring Pharmaceuticals Inc., Pacira Biosciences (Flexion Therapeutics, Inc. ), Pfizer Inc., Sanofi S. A., Teva Pharmaceuticals, Zimmer Biomet and among others.
Joint pain injections refer to the non-surgical procedures that involves application of the medication directly to damage joint tissue. Joint pain is defined as the discomfort caused into the joints which is associated with the various reasons including the arthritis and its different kinds, the previous injuries to a joint, overuse of the muscle, depression, anxiety, stress, and obesity. Furthermore, interleukin inhibitors are one of the most common types of therapeutic injections that include an anesthetic agent combined with a corticosteroid to relieve joint pain and inflammation.
According to the Arthritis Foundation, as of the numbers generated in 2022 there are about 60 million adults who have been diagnosed with arthritis and 1 in 4 adults have one of these types of arthritis. This rise in incidence of arthritis among all age groups owing to a sedentary lifestyle, rise in obesity, injuries due to physical activities and stress, will lead to the sales of the joint pain injection on a large scale.
Furthermore, the joint pain injections market is anticipated to grow by the introduction of numerous cutting-edge treatment technologies by the pharmaceutical companies, an increase in the demand for accurate treatment options by the patients, and the availability of high income in the developed economies.
Arthritis Foundation also states that, the inflammatory and rheumatic diseases that develops in children under the age of 16 is known to be juvenile arthritis, which affects nearly 300,000 kids and teens in the U. S. However, the government of Australia has published ‘The National Strategic Action Plan for Arthritis’ that aims to guide national efforts to address the burden of arthritis. Thus, such more initiatives and funding provided by the government will boost the growth of the market.
In addition, the rise in investment for research and development of the advanced and precise treatment options by public and private players in the market with an aim to improve health care infrastructure, due to the rise in the prevalence of the arthritis, along with rise in the obesity and geriatric patients are the key factors for the expansion of the joint pain injections market. For instance, the U. S. FDA approval for the second indication for Skyrizi (risankizumab-rzaa) to treat adults with active psoriatic arthritis that can be administered with a single injection four times a year.
However, the market is expected to be significantly constrained in the near future by factors such as lack of awareness about these injections in developing nations, their expensive price, and lack of reimbursement policies that effects the adoption of the products in the emerging countries. However, the key market players are developing more efficient treatment options which includes the single injection therapy and plasma matrix therapy, which will provide lucrative opportunities during the forecast period.
The joint pain injections market is segmented on the basis of injection type, by joint type, by distribution channel and region. By injection type, it is divided into interleukin inhibitors, hyaluronic acid injections and others. On the basis of joint type, the market is segmented into knee & ankle, hip joint, shoulder & elbow, facet joints of the spine and others. According to the distribution channel, the market is segmented into hospital pharmacies, drug stores & retail pharmacies and online providers. Further, the hospital pharmacies segment is divided into public hospital pharmacies and private hospital pharmacies. Region wise, it is analyzed across North America, Europe, Asia-Pacific, and LAMEA.
The major companies profiled in this report include Abbvie Inc., Anika Therapeutics Inc., Bioventus Inc., Eli Lilly and Company, Ferring Pharmaceuticals Inc., Pacira Biosciences (Flexion Therapeutics, Inc. ), Pfizer Inc., Sanofi S. A., Teva Pharmaceuticals, Zimmer Biomet and among others.
KEY BENEFITS FOR STAKEHOLDERS
- This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the joint pain injections market analysis from 2021 to 2031 to identify the prevailing joint pain injections market opportunities.
- The market research is offered along with information related to key drivers, restraints, and opportunities.
- Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.
- In-depth analysis of the joint pain injections market segmentation assists to determine the prevailing market opportunities.
- Major countries in each region are mapped according to their revenue contribution to the global market.
- Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
- The report includes the analysis of the regional as well as global joint pain injections market trends, key players, market segments, application areas, and market growth strategies.
Key Market Segments
By Injection Type
- Interleukin Inhibitors
- Hyaluronic Acid Injections
- Others
By Joint Type
- Knee and Ankle
- Hip Joint
- Shoulder and Elbow
- Facet Joints of the Spine
- Others
By Distribution Channel
- Hospital Pharmacies
- Type
- Public Hospital Pharmacies
- Private Hospital Pharmacies
- Drug Stores and Retail Pharmacies
- Online Providers
By Region
- North America
- U. S.
- Canada
- Mexico
- Europe
- Germany
- France
- UK
- Italy
- Spain
- Rest of Europe
- Asia-Pacific
- Japan
- China
- Australia
- India
- South Korea
- Rest of Asia-Pacific
- LAMEA
- Brazil
- Saudi Arabia
- South Africa
- Rest of LAMEA
Key Market Players
- Abbvie Inc
- Anika Therapeutics
- Bioventus
- Eli Lilly and Company
- Ferring Pharmaceuticals Inc.
- PACIRA BIOSCIENCES (Flexion Therapeutics, Inc. )
- Pfizer Inc.
- Sanofi S. A.
- Teva Pharmaceuticals
- Zimmer Biomet
Table of Contents
CHAPTER 1: INTRODUCTION1.1. Report description
1.2. Key market segments
1.3. Key benefits to the stakeholders
1.4. Research Methodology
1.4.1. Secondary research
1.4.2. Primary research
1.4.3. Analyst tools and models
CHAPTER 2: EXECUTIVE SUMMARY
2.1. Key findings of the study
2.2. CXO Perspective
CHAPTER 3: MARKET OVERVIEW
3.1. Market definition and scope
3.2. Key findings
3.2.1. Top investment pockets
3.3. Porter’s five forces analysis
3.4. Top player positioning
3.5. Market dynamics
3.5.1. Drivers
3.5.2. Restraints
3.5.3. Opportunities
3.6. COVID-19 Impact Analysis on the market
3.7. Patent Landscape
CHAPTER 4: JOINT PAIN INJECTIONS MARKET, BY INJECTION TYPE
4.1 Overview
4.1.1 Market size and forecast
4.2 Interleukin Inhibitors
4.2.1 Key market trends, growth factors and opportunities
4.2.2 Market size and forecast, by region
4.2.3 Market analysis by country
4.3 Hyaluronic Acid Injections
4.3.1 Key market trends, growth factors and opportunities
4.3.2 Market size and forecast, by region
4.3.3 Market analysis by country
4.4 Others
4.4.1 Key market trends, growth factors and opportunities
4.4.2 Market size and forecast, by region
4.4.3 Market analysis by country
CHAPTER 5: JOINT PAIN INJECTIONS MARKET, BY JOINT TYPE
5.1 Overview
5.1.1 Market size and forecast
5.2 Knee and Ankle
5.2.1 Key market trends, growth factors and opportunities
5.2.2 Market size and forecast, by region
5.2.3 Market analysis by country
5.3 Hip Joint
5.3.1 Key market trends, growth factors and opportunities
5.3.2 Market size and forecast, by region
5.3.3 Market analysis by country
5.4 Shoulder and Elbow
5.4.1 Key market trends, growth factors and opportunities
5.4.2 Market size and forecast, by region
5.4.3 Market analysis by country
5.5 Facet Joints of the Spine
5.5.1 Key market trends, growth factors and opportunities
5.5.2 Market size and forecast, by region
5.5.3 Market analysis by country
5.6 Others
5.6.1 Key market trends, growth factors and opportunities
5.6.2 Market size and forecast, by region
5.6.3 Market analysis by country
CHAPTER 6: JOINT PAIN INJECTIONS MARKET, BY DISTRIBUTION CHANNEL
6.1 Overview
6.1.1 Market size and forecast
6.2 Hospital Pharmacies
6.2.1 Key market trends, growth factors and opportunities
6.2.2 Market size and forecast, by region
6.2.3 Market analysis by country
6.2.4 Hospital Pharmacies Joint Pain Injections Market by Type
6.2.4.1 Public Hospital Pharmacies Market size and forecast, by region
6.2.4.2 Private Hospital Pharmacies Market size and forecast, by region
6.3 Drug Stores and Retail Pharmacies
6.3.1 Key market trends, growth factors and opportunities
6.3.2 Market size and forecast, by region
6.3.3 Market analysis by country
6.4 Online Providers
6.4.1 Key market trends, growth factors and opportunities
6.4.2 Market size and forecast, by region
6.4.3 Market analysis by country
CHAPTER 7: JOINT PAIN INJECTIONS MARKET, BY REGION
7.1 Overview
7.1.1 Market size and forecast
7.2 North America
7.2.1 Key trends and opportunities
7.2.2 North America Market size and forecast, by Injection Type
7.2.3 North America Market size and forecast, by Joint Type
7.2.4 North America Market size and forecast, by Distribution Channel
7.2.4.1 North America Hospital Pharmacies Joint Pain Injections Market by Type
7.2.5 North America Market size and forecast, by country
7.2.5.1 U. S.
7.2.5.1.1 Market size and forecast, by Injection Type
7.2.5.1.2 Market size and forecast, by Joint Type
7.2.5.1.3 Market size and forecast, by Distribution Channel
7.2.5.2 Canada
7.2.5.2.1 Market size and forecast, by Injection Type
7.2.5.2.2 Market size and forecast, by Joint Type
7.2.5.2.3 Market size and forecast, by Distribution Channel
7.2.5.3 Mexico
7.2.5.3.1 Market size and forecast, by Injection Type
7.2.5.3.2 Market size and forecast, by Joint Type
7.2.5.3.3 Market size and forecast, by Distribution Channel
7.3 Europe
7.3.1 Key trends and opportunities
7.3.2 Europe Market size and forecast, by Injection Type
7.3.3 Europe Market size and forecast, by Joint Type
7.3.4 Europe Market size and forecast, by Distribution Channel
7.3.4.1 Europe Hospital Pharmacies Joint Pain Injections Market by Type
7.3.5 Europe Market size and forecast, by country
7.3.5.1 Germany
7.3.5.1.1 Market size and forecast, by Injection Type
7.3.5.1.2 Market size and forecast, by Joint Type
7.3.5.1.3 Market size and forecast, by Distribution Channel
7.3.5.2 France
7.3.5.2.1 Market size and forecast, by Injection Type
7.3.5.2.2 Market size and forecast, by Joint Type
7.3.5.2.3 Market size and forecast, by Distribution Channel
7.3.5.3 UK
7.3.5.3.1 Market size and forecast, by Injection Type
7.3.5.3.2 Market size and forecast, by Joint Type
7.3.5.3.3 Market size and forecast, by Distribution Channel
7.3.5.4 Italy
7.3.5.4.1 Market size and forecast, by Injection Type
7.3.5.4.2 Market size and forecast, by Joint Type
7.3.5.4.3 Market size and forecast, by Distribution Channel
7.3.5.5 Spain
7.3.5.5.1 Market size and forecast, by Injection Type
7.3.5.5.2 Market size and forecast, by Joint Type
7.3.5.5.3 Market size and forecast, by Distribution Channel
7.3.5.6 Rest of Europe
7.3.5.6.1 Market size and forecast, by Injection Type
7.3.5.6.2 Market size and forecast, by Joint Type
7.3.5.6.3 Market size and forecast, by Distribution Channel
7.4 Asia-Pacific
7.4.1 Key trends and opportunities
7.4.2 Asia-Pacific Market size and forecast, by Injection Type
7.4.3 Asia-Pacific Market size and forecast, by Joint Type
7.4.4 Asia-Pacific Market size and forecast, by Distribution Channel
7.4.4.1 Asia-Pacific Hospital Pharmacies Joint Pain Injections Market by Type
7.4.5 Asia-Pacific Market size and forecast, by country
7.4.5.1 Japan
7.4.5.1.1 Market size and forecast, by Injection Type
7.4.5.1.2 Market size and forecast, by Joint Type
7.4.5.1.3 Market size and forecast, by Distribution Channel
7.4.5.2 China
7.4.5.2.1 Market size and forecast, by Injection Type
7.4.5.2.2 Market size and forecast, by Joint Type
7.4.5.2.3 Market size and forecast, by Distribution Channel
7.4.5.3 Australia
7.4.5.3.1 Market size and forecast, by Injection Type
7.4.5.3.2 Market size and forecast, by Joint Type
7.4.5.3.3 Market size and forecast, by Distribution Channel
7.4.5.4 India
7.4.5.4.1 Market size and forecast, by Injection Type
7.4.5.4.2 Market size and forecast, by Joint Type
7.4.5.4.3 Market size and forecast, by Distribution Channel
7.4.5.5 South Korea
7.4.5.5.1 Market size and forecast, by Injection Type
7.4.5.5.2 Market size and forecast, by Joint Type
7.4.5.5.3 Market size and forecast, by Distribution Channel
7.4.5.6 Rest of Asia-Pacific
7.4.5.6.1 Market size and forecast, by Injection Type
7.4.5.6.2 Market size and forecast, by Joint Type
7.4.5.6.3 Market size and forecast, by Distribution Channel
7.5 LAMEA
7.5.1 Key trends and opportunities
7.5.2 LAMEA Market size and forecast, by Injection Type
7.5.3 LAMEA Market size and forecast, by Joint Type
7.5.4 LAMEA Market size and forecast, by Distribution Channel
7.5.4.1 LAMEA Hospital Pharmacies Joint Pain Injections Market by Type
7.5.5 LAMEA Market size and forecast, by country
7.5.5.1 Brazil
7.5.5.1.1 Market size and forecast, by Injection Type
7.5.5.1.2 Market size and forecast, by Joint Type
7.5.5.1.3 Market size and forecast, by Distribution Channel
7.5.5.2 Saudi Arabia
7.5.5.2.1 Market size and forecast, by Injection Type
7.5.5.2.2 Market size and forecast, by Joint Type
7.5.5.2.3 Market size and forecast, by Distribution Channel
7.5.5.3 South Africa
7.5.5.3.1 Market size and forecast, by Injection Type
7.5.5.3.2 Market size and forecast, by Joint Type
7.5.5.3.3 Market size and forecast, by Distribution Channel
7.5.5.4 Rest of LAMEA
7.5.5.4.1 Market size and forecast, by Injection Type
7.5.5.4.2 Market size and forecast, by Joint Type
7.5.5.4.3 Market size and forecast, by Distribution Channel
CHAPTER 8: COMPANY LANDSCAPE
8.1. Introduction
8.2. Top winning strategies
8.3. Product Mapping of Top 10 Players
8.4. Competitive Dashboard
8.5. Competitive Heatmap
8.6. Key developments
CHAPTER 9: COMPANY PROFILES
9.1 Abbvie Inc
9.1.1 Company overview
9.1.2 Company snapshot
9.1.3 Operating business segments
9.1.4 Product portfolio
9.1.5 Business performance
9.1.6 Key strategic moves and developments
9.2 Anika Therapeutics
9.2.1 Company overview
9.2.2 Company snapshot
9.2.3 Operating business segments
9.2.4 Product portfolio
9.2.5 Business performance
9.2.6 Key strategic moves and developments
9.3 Bioventus
9.3.1 Company overview
9.3.2 Company snapshot
9.3.3 Operating business segments
9.3.4 Product portfolio
9.3.5 Business performance
9.3.6 Key strategic moves and developments
9.4 Eli Lilly and Company
9.4.1 Company overview
9.4.2 Company snapshot
9.4.3 Operating business segments
9.4.4 Product portfolio
9.4.5 Business performance
9.4.6 Key strategic moves and developments
9.5 Ferring Pharmaceuticals Inc.
9.5.1 Company overview
9.5.2 Company snapshot
9.5.3 Operating business segments
9.5.4 Product portfolio
9.5.5 Business performance
9.5.6 Key strategic moves and developments
9.6 PACIRA BIOSCIENCES (Flexion Therapeutics, Inc.)
9.6.1 Company overview
9.6.2 Company snapshot
9.6.3 Operating business segments
9.6.4 Product portfolio
9.6.5 Business performance
9.6.6 Key strategic moves and developments
9.7 Pfizer Inc.
9.7.1 Company overview
9.7.2 Company snapshot
9.7.3 Operating business segments
9.7.4 Product portfolio
9.7.5 Business performance
9.7.6 Key strategic moves and developments
9.8 Sanofi S. A.
9.8.1 Company overview
9.8.2 Company snapshot
9.8.3 Operating business segments
9.8.4 Product portfolio
9.8.5 Business performance
9.8.6 Key strategic moves and developments
9.9 Teva Pharmaceuticals
9.9.1 Company overview
9.9.2 Company snapshot
9.9.3 Operating business segments
9.9.4 Product portfolio
9.9.5 Business performance
9.9.6 Key strategic moves and developments
9.10 Zimmer Biomet
9.10.1 Company overview
9.10.2 Company snapshot
9.10.3 Operating business segments
9.10.4 Product portfolio
9.10.5 Business performance
9.10.6 Key strategic moves and developments
Executive Summary
According to this report, titled, 'Joint Pain Injections Market,' The joint pain injections market was valued at $6,271.91 million in 2021, and is projected to reach $13,176.31 million by 2031, growing at a CAGR of 7.7% from 2022 to 2031.Joint pain treatments basically include the joint pain injections that proves to be an efficient treatment option. This includes the steroid injection that contains both a corticosteroid and an anesthetic numbing agent. The drugs are basically delivered to the painful joint inside the joint capsule. Joint pain injections are used to treat pain caused due to the various reasons including the arthritis and its different kinds, the previous injuries to a joint, overuse of the muscle, depression, anxiety, stress, and obesity
Key factors driving the growth of the joint pain injections include growth in prevalence of arthritis, increase in prevalence of obesity leading to joint pain and rise in the geriatric population. In addition, rise in prevalence of obesity and rise in occurrence of bone and muscle related disorders across all age groups, together with the involvement of major businesses in the production of joint pain injections, are projected to drive the market's growth throughout the forecast period. Overweight and obesity are one of the main causes for health impairment. According to World Health Organization (WHO), obesity may lead to various serious disorders including the cardiovascular diseases, diabetes, musculoskeletal disorders and others. Therefore, increase in obesity leads to the increase in cases of musculoskeletal disorders such as osteoarthritis, which may lead to joint pain in the person. This increases the demand for joint pain injections for the treatment of such disorders. Thus propels the growth of the market.
Rise in prevalence of the rheumatoid arthritis cases around the globe, leads to the increase in the demand for the joint pain injections. In addition, the rise in the prevalence of asthma and musculoskeletal disorders, rise in the awareness about the interleukin inhibitors injections along with the wide range of products offered by the key market players will propel the growth of the joint pain injections market.
Furthermore, increasing R&D activities by the key market players, and advancements in pharmaceuticals field is anticipated to offer lucrative opportunity for the market growth. Advancements in joint pain injection such as single injection therapy and plasma matrix therapy, will provide lucrative opportunities for the market players to invest and also leads to the market growth. The key market players are investing on a large scale in research activities which results in innovative products with better efficacy and faster results. In addition, key players from the developed region are focusing on investment in emerging economies like Asia and LAMEA regions, owing to the abundance of raw materials for manufacturing of products. These factors are anticipated to boost the market during the forecast period.
The joint pain injections market is segmented on the basis of injection type, by joint type, by distribution channel and region. By injection type, it is divided into interleukin inhibitors, hyaluronic acid injections and others. On the basis of joint type, the market is segmented into knee & ankle, hip joint, shoulder & elbow, facet joints of the spine and others. According to the distribution channel, the market is segmented into hospital pharmacies, drug stores & retail pharmacies and online providers. Region wise, it is analyzed across North America (the U.S., Canada, and Mexico), Europe (the UK, Germany, France, Italy, Spain, and rest of Europe), Asia-Pacific (China, India, Japan, Australia, South Korea and rest of Asia-Pacific), and LAMEA (Brazil, Saudi Arabia, South Africa, and rest of LAMEA).
The key players profiled in the study include Abbvie Inc., Anika Therapeutics Inc., Bioventus Inc., Eli Lilly and Company, Ferring Pharmaceuticals Inc., Pacira Biosciences (Flexion Therapeutics, Inc.), Pfizer Inc., Sanofi S.A., Teva Pharmaceuticals, Zimmer Biomet. The players in the market have been actively engaged in the adoption various strategies such as product launch, product approval, product development, business expansion and acquisition to remain competitive and gain advantage over the competitors in the market. For instance, in August 2022, Eli Lilly and Company announced the launch of a new, citrate-free formulation of Taltz (ixekizumab) injection approved to treat adults and children six years and older with moderate to severe plaque psoriasis who are candidates for systemic therapy or phototherapy, and adults with active psoriatic arthritis.
Key Market Insights
- By injection type, the interleukin inhibitors segment was the highest revenue contributor to the market and is estimated to reach $6798.99 million by 2031, with a CAGR of 8.7%. However, the hyaluronic acid segment is estimated to be the fastest-growing segment with a CAGR of 14.7% during the forecast period.
- By joint type, the knee and ankle segment dominated the global market. However, the hip joint segment is expected to be the fastest-growing segment with a CAGR of 8.8% during the forecast period.
- Based on distribution channel, the Drug Stores and Retail Pharmacies segment was the highest revenue contributor to the market and the online providers segment is anticipated to grow with highest CAGR during the forecast period.
- Based on region, North America garnered the largest revenue share in 2021, whereas Asia-Pacific is anticipated to grow at the highest CAGR of 9.5% during the forecast period
Companies Mentioned
- Abbvie Inc.
- Anika Therapeutics
- Bioventus
- Eli Lilly and Company
- Ferring Pharmaceuticals Inc.
- Pacira Biosciences (Flexion Therapeutics, Inc.)
- Pfizer Inc.
- Sanofi SA
- Teva Pharmaceuticals
- Zimmer Biomet
Methodology
The analyst offers exhaustive research and analysis based on a wide variety of factual inputs, which largely include interviews with industry participants, reliable statistics, and regional intelligence. The in-house industry experts play an instrumental role in designing analytic tools and models, tailored to the requirements of a particular industry segment. The primary research efforts include reaching out participants through mail, tele-conversations, referrals, professional networks, and face-to-face interactions.
They are also in professional corporate relations with various companies that allow them greater flexibility for reaching out to industry participants and commentators for interviews and discussions.
They also refer to a broad array of industry sources for their secondary research, which typically include; however, not limited to:
- Company SEC filings, annual reports, company websites, broker & financial reports, and investor presentations for competitive scenario and shape of the industry
- Scientific and technical writings for product information and related preemptions
- Regional government and statistical databases for macro analysis
- Authentic news articles and other related releases for market evaluation
- Internal and external proprietary databases, key market indicators, and relevant press releases for market estimates and forecast
Furthermore, the accuracy of the data will be analyzed and validated by conducting additional primaries with various industry experts and KOLs. They also provide robust post-sales support to clients.
LOADING...
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 310 |
| Published | November 2022 |
| Forecast Period | 2021 - 2031 |
| Estimated Market Value ( USD | $ 6271.91 million |
| Forecasted Market Value ( USD | $ 13176.31 million |
| Compound Annual Growth Rate | 7.7% |
| Regions Covered | Global |
| No. of Companies Mentioned | 10 |
